Deferred Tax Assets, Net of Valuation Allowance of 10x Genomics, Inc. from 31 Dec 2018 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
- Summary
-
10x Genomics, Inc. quarterly Deferred Tax Assets, Net of Valuation Allowance in USD history and change rate from 31 Dec 2018 to 31 Dec 2025.
- 10x Genomics, Inc. Deferred Tax Assets, Net of Valuation Allowance for the quarter ending 31 Dec 2025 was $15,686,000, a 6.2% decline year-over-year.
- Source SEC data
- View on sec.gov
Deferred Tax Assets, Net of Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Net of Valuation Allowance, YoY Quarterly Change (%)
10x Genomics, Inc. Quarterly Deferred Tax Assets, Net of Valuation Allowance (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | $15,686,000 | -$1,033,000 | -6.2% | 31 Dec 2025 | 10-K | 13 Feb 2026 | 2025 | FY |
| Q4 2024 | $16,719,000 | -$659,000 | -3.8% | 31 Dec 2024 | 10-K | 13 Feb 2026 | 2025 | FY |
| Q4 2023 | $17,378,000 | -$1,070,000 | -5.8% | 31 Dec 2023 | 10-K | 13 Feb 2025 | 2024 | FY |
| Q4 2022 | $18,448,000 | +$1,030,000 | +5.9% | 31 Dec 2022 | 10-K | 15 Feb 2024 | 2023 | FY |
| Q4 2021 | $17,418,000 | +$3,355,000 | +24% | 31 Dec 2021 | 10-K | 16 Feb 2023 | 2022 | FY |
| Q4 2020 | $14,063,000 | +$9,110,000 | +184% | 31 Dec 2020 | 10-K | 18 Feb 2022 | 2021 | FY |
| Q4 2019 | $4,953,000 | +$4,493,000 | +977% | 31 Dec 2019 | 10-K | 26 Feb 2021 | 2020 | FY |
| Q4 2018 | $460,000 | 31 Dec 2018 | 10-K | 27 Feb 2020 | 2019 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.